A cost-effectiveness analysis evaluated the impact of newer antiobesity medications like tirzepatide and semaglutide on long-term health benefits. The study projected substantial reductions in obesity, diabetes, and cardiovascular disease cases but highlighted that the medications do not meet standard cost-effectiveness thresholds at current net prices. Efforts to reduce the prices of these medications were deemed essential for equitable access. The findings support ongoing efforts to address the high net prices of antiobesity medications, which could exacerbate obesity disparities.

Source: JAMA Health Forum